Zolpidem Use and Hip Fractures in Older People

OBJECTIVES: The widespread use of sedative‐hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpide...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Geriatrics Society (JAGS) Vol. 49; no. 12; pp. 1685 - 1690
Main Authors Wang, Philip S., Bohn, Rhonda L., Glynn, Robert J., Mogun, Helen, Avorn, Jerry
Format Journal Article
LanguageEnglish
Published Boston, MA, USA Blackwell Science Inc 01.12.2001
Blackwell
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN0002-8614
1532-5415
DOI10.1111/j.1532-5415.2001.49280.x

Cover

Abstract OBJECTIVES: The widespread use of sedative‐hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative. DESIGN: Case‐control study of hip fracture cases and controls in 1994. SETTING: All subjects were age 65 and older and enrolled in Medicare, and in Medicaid or the Pharmaceutical Assistance to the Aged and Disabled program of New Jersey. PARTICIPANTS: Cases (n = 1,222) were patients who underwent surgical repair of a hip fracture. They were frequency‐matched to four controls (n = 4,888) based on age and gender. MEASUREMENTS: Use of sedative‐hypnotics and other medications was assessed in the 180 days before the index event. We assessed other covariates, including demographic, clinical, and healthcare utilization variables in the prior 180 days. RESULTS: Zolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1.95; 95% confidence interval (CI) = 1.09–3.51). Other psychotropic medication classes with significantly increased risks included benzodiazepines (AOR 1.46; 95% CI = 1.21–1.76), antipsychotic medications (AOR 1.61; 95% CI = 1.29–2.01), and antidepressants (AOR 1.46; 95% CI = 1.22–1.75). In subanalyses, preferential use of zolpidem by subjects at greater risk of hip fracture did not appear to explain the apparent risk of hip fracture with zolpidem use. CONCLUSION: Use of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients.
AbstractList The widespread use of sedative-hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative.OBJECTIVESThe widespread use of sedative-hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative.Case-control study of hip fracture cases and controls in 1994.DESIGNCase-control study of hip fracture cases and controls in 1994.All subjects were age 65 and older and enrolled in Medicare, and in Medicaid or the Pharmaceutical Assistance to the Aged and Disabled program of New Jersey.SETTINGAll subjects were age 65 and older and enrolled in Medicare, and in Medicaid or the Pharmaceutical Assistance to the Aged and Disabled program of New Jersey.Cases (n=1,222) were patients who underwent surgical repair of a hip fracture. They were frequency-matched to four controls (n=4,888) based on age and gender.PARTICIPANTSCases (n=1,222) were patients who underwent surgical repair of a hip fracture. They were frequency-matched to four controls (n=4,888) based on age and gender.Use of sedative-hypnotics and other medications was assessed in the 180 days before the index event. We assessed other covariates, including demographic, clinical, and healthcare utilization variables in the prior 180 days.MEASUREMENTSUse of sedative-hypnotics and other medications was assessed in the 180 days before the index event. We assessed other covariates, including demographic, clinical, and healthcare utilization variables in the prior 180 days.Zolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1.95; 95% confidence interval (CI)=1.09-3.51). Other psychotropic medication classes with significantly increased risks included benzodiazepines (AOR 1.46; 95% CI=1.21-1.76), antipsychotic medications (AOR 1.61; 95% CI=1.29-2.01), and antidepressants (AOR 1.46; 95% CI=1.22-1.75). In subanalyses, preferential use of zolpidem by subjects at greater risk of hip fracture did not appear to explain the apparent risk of hip fracture with zolpidem use.RESULTSZolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1.95; 95% confidence interval (CI)=1.09-3.51). Other psychotropic medication classes with significantly increased risks included benzodiazepines (AOR 1.46; 95% CI=1.21-1.76), antipsychotic medications (AOR 1.61; 95% CI=1.29-2.01), and antidepressants (AOR 1.46; 95% CI=1.22-1.75). In subanalyses, preferential use of zolpidem by subjects at greater risk of hip fracture did not appear to explain the apparent risk of hip fracture with zolpidem use.Use of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients.CONCLUSIONUse of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients.
Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic has been advocated as a safer alternative. Finds that use of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients. (Original abstract - amended)
The widespread use of sedative-hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative.
OBJECTIVES: The widespread use of sedative‐hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative. DESIGN: Case‐control study of hip fracture cases and controls in 1994. SETTING: All subjects were age 65 and older and enrolled in Medicare, and in Medicaid or the Pharmaceutical Assistance to the Aged and Disabled program of New Jersey. PARTICIPANTS: Cases (n = 1,222) were patients who underwent surgical repair of a hip fracture. They were frequency‐matched to four controls (n = 4,888) based on age and gender. MEASUREMENTS: Use of sedative‐hypnotics and other medications was assessed in the 180 days before the index event. We assessed other covariates, including demographic, clinical, and healthcare utilization variables in the prior 180 days. RESULTS: Zolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1.95; 95% confidence interval (CI) = 1.09–3.51). Other psychotropic medication classes with significantly increased risks included benzodiazepines (AOR 1.46; 95% CI = 1.21–1.76), antipsychotic medications (AOR 1.61; 95% CI = 1.29–2.01), and antidepressants (AOR 1.46; 95% CI = 1.22–1.75). In subanalyses, preferential use of zolpidem by subjects at greater risk of hip fracture did not appear to explain the apparent risk of hip fracture with zolpidem use. CONCLUSION: Use of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients.
OBJECTIVES: The widespread use of sedative‐hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative. DESIGN: Case‐control study of hip fracture cases and controls in 1994. SETTING: All subjects were age 65 and older and enrolled in Medicare, and in Medicaid or the Pharmaceutical Assistance to the Aged and Disabled program of New Jersey. PARTICIPANTS: Cases (n = 1,222) were patients who underwent surgical repair of a hip fracture. They were frequency‐matched to four controls (n = 4,888) based on age and gender. MEASUREMENTS: Use of sedative‐hypnotics and other medications was assessed in the 180 days before the index event. We assessed other covariates, including demographic, clinical, and healthcare utilization variables in the prior 180 days. RESULTS: Zolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1.95; 95% confidence interval (CI) = 1.09–3.51). Other psychotropic medication classes with significantly increased risks included benzodiazepines (AOR 1.46; 95% CI = 1.21–1.76), antipsychotic medications (AOR 1.61; 95% CI = 1.29–2.01), and antidepressants (AOR 1.46; 95% CI = 1.22–1.75). In subanalyses, preferential use of zolpidem by subjects at greater risk of hip fracture did not appear to explain the apparent risk of hip fracture with zolpidem use. CONCLUSION: Use of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients.
The widespread use of sedative-hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that may be used preferentially by older people. Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic, has been advocated as a safer alternative. Case-control study of hip fracture cases and controls in 1994. All subjects were age 65 and older and enrolled in Medicare, and in Medicaid or the Pharmaceutical Assistance to the Aged and Disabled program of New Jersey. Cases (n=1,222) were patients who underwent surgical repair of a hip fracture. They were frequency-matched to four controls (n=4,888) based on age and gender. Use of sedative-hypnotics and other medications was assessed in the 180 days before the index event. We assessed other covariates, including demographic, clinical, and healthcare utilization variables in the prior 180 days. Zolpidem use was associated with a significant increased risk of hip fracture (adjusted odds ratio (AOR) 1.95; 95% confidence interval (CI)=1.09-3.51). Other psychotropic medication classes with significantly increased risks included benzodiazepines (AOR 1.46; 95% CI=1.21-1.76), antipsychotic medications (AOR 1.61; 95% CI=1.29-2.01), and antidepressants (AOR 1.46; 95% CI=1.22-1.75). In subanalyses, preferential use of zolpidem by subjects at greater risk of hip fracture did not appear to explain the apparent risk of hip fracture with zolpidem use. Use of zolpidem by older people was associated with nearly twice the risk of hip fracture, even after controlling for possible demographic and clinical confounders. Rather than being a safer alternative, zolpidem may be associated with risks that are as great as those seen with conventional benzodiazepines in older patients.
Author Avorn, Jerry
Glynn, Robert J.
Wang, Philip S.
Bohn, Rhonda L.
Mogun, Helen
Author_xml – sequence: 1
  givenname: Philip S.
  surname: Wang
  fullname: Wang, Philip S.
  organization: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
– sequence: 2
  givenname: Rhonda L.
  surname: Bohn
  fullname: Bohn, Rhonda L.
  organization: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
– sequence: 3
  givenname: Robert J.
  surname: Glynn
  fullname: Glynn, Robert J.
  organization: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
– sequence: 4
  givenname: Helen
  surname: Mogun
  fullname: Mogun, Helen
  organization: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
– sequence: 5
  givenname: Jerry
  surname: Avorn
  fullname: Avorn, Jerry
  organization: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13413514$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11844004$$D View this record in MEDLINE/PubMed
BookMark eNqV0U9rFDEYBvAgFbutfgUZBL3NmDd_dpKLoMVuK2Vb0KL0EjJJFrJmZ8ZkBrff3kx320Ivai4J5JcnJM8ROmi71iFUAK4gj_frCjglJWfAK4IxVEwSgavtMzR72DhAM4wxKcUc2CE6SmmdIcFCvECHAIIxjNkMVTdd6L11m-I6uUK3tjjzfXEatRnG6FLh2-IyWBeLK9f1wb1Ez1c6JPdqPx-j69PP307OyovLxfnJx4vScC5wSaixUjLcME24AU4MOMKBu3pFGyK1FQxLQ8BiYcBK2gC2rm6s1ELquQZ6jN7tcvvY_RpdGtTGJ-NC0K3rxqRqwqikbP5XyGsBQhKa4ZsncN2Nsc2PUAQwFTmLZPR6j8Zm46zqo9_oeKvu_yuDt3ugk9FhFXVrfHp0lAHlMDmxcyZ2KUW3eiRYTRWqtZqaUlNTaqpQ3VWotvnohydHjR_04Lt2iNqH_wj47YO7_eeL1ZfF17tlDih3AT4NbvsQoONPNa9pzdX35UL9WNKlkFc36hP9A3WUv6o
CODEN JAGSAF
CitedBy_id crossref_primary_10_1038_s41598_019_56108_4
crossref_primary_10_1097_JCP_0b013e31817d5943
crossref_primary_10_1136_bmjopen_2012_000850
crossref_primary_10_1111_j_1365_2796_2006_01695_x
crossref_primary_10_1007_s00198_013_2612_2
crossref_primary_10_1016_j_mayocp_2014_03_006
crossref_primary_10_1111_j_1532_5415_2011_03591_x
crossref_primary_10_1155_2022_6168199
crossref_primary_10_1002_14651858_CD005185_pub2
crossref_primary_10_2146_ajhp090611
crossref_primary_10_1007_s00108_010_2647_9
crossref_primary_10_2165_00023210_200721110_00006
crossref_primary_10_1016_j_jcgg_2012_12_001
crossref_primary_10_1007_s40520_022_02237_2
crossref_primary_10_1111_jgs_15438
crossref_primary_10_1002_mpr_1384
crossref_primary_10_2217_pgs_2017_0018
crossref_primary_10_1002_pds_1200
crossref_primary_10_1007_s40429_018_0218_7
crossref_primary_10_1016_j_brat_2013_09_006
crossref_primary_10_21037_ajo_2019_03_01
crossref_primary_10_1002_pds_4706
crossref_primary_10_1016_j_exger_2020_110962
crossref_primary_10_1007_s13181_013_0294_y
crossref_primary_10_1007_s00198_005_0065_y
crossref_primary_10_1016_j_sleep_2006_01_003
crossref_primary_10_1517_14728214_2012_690735
crossref_primary_10_1007_s00198_008_0711_2
crossref_primary_10_2217_ahe_13_34
crossref_primary_10_5812_ijpbs_9979
crossref_primary_10_1186_s12877_022_02757_6
crossref_primary_10_1016_j_cger_2007_08_012
crossref_primary_10_1016_j_eurger_2012_04_007
crossref_primary_10_1111_jgs_13823
crossref_primary_10_1111_j_1755_5949_2010_00158_x
crossref_primary_10_1080_13696998_2018_1466710
crossref_primary_10_1093_sleep_zsab064
crossref_primary_10_1007_s00391_017_1329_9
crossref_primary_10_1002_jhm_1985
crossref_primary_10_1007_s11096_017_0533_4
crossref_primary_10_1186_s12877_018_0972_3
crossref_primary_10_1016_j_bone_2005_07_005
crossref_primary_10_1097_JGP_0b013e31817c6a99
crossref_primary_10_1093_sleep_zsaa093
crossref_primary_10_1177_0898264315618921
crossref_primary_10_1111_j_1745_7599_2007_00285_x
crossref_primary_10_1111_j_1532_5415_2006_01006_x
crossref_primary_10_1177_00914150221128971
crossref_primary_10_1177_104990910302000512
crossref_primary_10_1016_j_hfc_2010_08_009
crossref_primary_10_2165_00128413_200213240_00053
crossref_primary_10_1007_s00167_010_1368_x
crossref_primary_10_1046_j_0306_5251_2003_01852_x
crossref_primary_10_2165_00023210_200418050_00003
crossref_primary_10_1177_0897190019851888
crossref_primary_10_1200_JCO_2005_02_8514
crossref_primary_10_1002_pds_2031
crossref_primary_10_2165_00002018_200730020_00006
crossref_primary_10_2165_00002512_200623010_00003
crossref_primary_10_1016_j_cger_2017_06_009
crossref_primary_10_1016_S0924_9338_03_00031_2
crossref_primary_10_1016_j_amjopharm_2006_06_006
crossref_primary_10_1016_j_sleep_2008_04_002
crossref_primary_10_1111_j_1479_8425_2012_00573_x
crossref_primary_10_1016_j_ncl_2012_08_012
crossref_primary_10_1093_ageing_aft089
crossref_primary_10_1248_yakushi_18_00156
crossref_primary_10_1007_s00198_016_3881_3
crossref_primary_10_1056_NEJMoa052827
crossref_primary_10_1371_journal_pone_0191211
crossref_primary_10_1155_2019_4306463
crossref_primary_10_1097_01_ede_0000147164_11879_b5
crossref_primary_10_1007_s11910_006_0051_6
crossref_primary_10_1007_s00198_016_3605_8
crossref_primary_10_1371_journal_pone_0174730
crossref_primary_10_1002_j_2055_2335_2007_tb00754_x
crossref_primary_10_1002_hup_2219
crossref_primary_10_1016_j_clinthera_2006_08_006
crossref_primary_10_1517_14656566_2012_667074
crossref_primary_10_1016_j_ajem_2008_12_020
crossref_primary_10_1176_appi_ps_201700095
crossref_primary_10_1016_j_addbeh_2012_06_015
crossref_primary_10_2165_11317610_000000000_00000
crossref_primary_10_1586_17512433_2014_864949
crossref_primary_10_1016_j_injury_2021_09_036
crossref_primary_10_1089_pop_2008_0047
crossref_primary_10_1016_j_jamda_2009_10_001
crossref_primary_10_1345_aph_1Q589
crossref_primary_10_4140_TCP_n_2006_293
crossref_primary_10_2217_1745509X_2_1_87
crossref_primary_10_3349_ymj_2015_56_3_772
crossref_primary_10_1176_appi_ps_56_3_332
crossref_primary_10_1016_j_jamda_2017_09_015
crossref_primary_10_1007_s00228_021_03241_7
crossref_primary_10_1186_1478_7954_4_15
crossref_primary_10_2515_therapie_2005078
crossref_primary_10_1007_s40501_013_0004_z
crossref_primary_10_2165_00128415_200208880_00004
crossref_primary_10_1007_s00198_007_0375_3
crossref_primary_10_1007_s00198_013_2446_y
crossref_primary_10_1038_sj_ki_5002548
crossref_primary_10_12688_f1000research_8729_3
crossref_primary_10_1016_S1543_5946_04_90008_6
crossref_primary_10_12688_f1000research_8729_2
crossref_primary_10_12688_f1000research_8729_1
crossref_primary_10_1097_MJT_0000000000000670
crossref_primary_10_1093_gerona_62_10_1172
crossref_primary_10_1185_030079907X178874
crossref_primary_10_1248_yakushi_20_00018
crossref_primary_10_1097_01_jcp_0000145344_76288_39
crossref_primary_10_1371_journal_pone_0129366
crossref_primary_10_2174_1876818001001010001
crossref_primary_10_1016_j_ajem_2017_04_023
crossref_primary_10_1016_j_amjopharm_2007_09_004
crossref_primary_10_1186_1471_2318_4_9
crossref_primary_10_5664_jcsm_10132
crossref_primary_10_1007_s00198_012_2015_9
crossref_primary_10_1016_j_jhep_2012_12_001
crossref_primary_10_1097_NMD_0b013e3181e9daf7
crossref_primary_10_1016_j_smrv_2023_101866
crossref_primary_10_1016_j_jsmc_2014_11_002
crossref_primary_10_1371_journal_pone_0190022
crossref_primary_10_3389_fphar_2024_1432726
crossref_primary_10_1177_070674370605100504
crossref_primary_10_1186_1471_2318_8_15
crossref_primary_10_1073_pnas_1907354116
crossref_primary_10_1177_0091415016685330
crossref_primary_10_1146_annurev_med_57_071604_141451
crossref_primary_10_1007_s40266_018_0561_3
crossref_primary_10_1186_s12877_017_0530_4
crossref_primary_10_1371_journal_pone_0146030
crossref_primary_10_1007_s40268_017_0207_7
crossref_primary_10_1016_j_amjopharm_2011_10_002
crossref_primary_10_1016_S0029_6465_02_00028_2
crossref_primary_10_1007_s00223_012_9603_8
crossref_primary_10_1016_j_amjopharm_2009_05_002
crossref_primary_10_1111_jgs_15066
crossref_primary_10_1007_s40263_022_00980_8
crossref_primary_10_1186_s13063_017_2001_9
crossref_primary_10_47795_ESUV5344
crossref_primary_10_1111_jgs_14253
crossref_primary_10_1111_j_1532_5415_2005_53303_x
crossref_primary_10_1017_S1041610210001547
crossref_primary_10_1186_s40794_017_0054_0
crossref_primary_10_1002_gps_2569
crossref_primary_10_1016_j_jad_2011_10_016
crossref_primary_10_1016_S0749_0690_03_00044_2
crossref_primary_10_1177_0898264318795567
crossref_primary_10_1016_j_amjopharm_2006_09_010
crossref_primary_10_1016_j_amjopharm_2011_10_004
crossref_primary_10_1016_j_metabol_2017_12_002
crossref_primary_10_1093_sleep_zsaa080
crossref_primary_10_1016_S0140_6736_11_60750_2
crossref_primary_10_1002_j_2055_2335_2008_tb00823_x
crossref_primary_10_1016_j_bmcl_2005_05_104
crossref_primary_10_1007_s00213_021_05954_0
crossref_primary_10_1007_s00228_012_1424_1
crossref_primary_10_2165_00002512_200522090_00004
crossref_primary_10_1097_YIC_0000000000000221
crossref_primary_10_1007_s00223_004_0258_y
crossref_primary_10_3310_hta25010
crossref_primary_10_1111_j_1532_5415_2010_03229_x
crossref_primary_10_1002_gps_2189
crossref_primary_10_1016_j_jsmc_2009_01_012
crossref_primary_10_5665_sleep_3566
crossref_primary_10_5665_sleep_5742
crossref_primary_10_1097_MD_0000000000000809
crossref_primary_10_1038_sj_clpt_6100249
crossref_primary_10_1097_00013614_200607000_00005
crossref_primary_10_1136_dtb_2004_421289
crossref_primary_10_1002_pds_3951
crossref_primary_10_1002_14651858_CD010703_pub2
Cites_doi 10.1177/026988119901300109
10.1001/jama.262.23.3303
10.1016/S0924-9338(97)80017-X
10.1097/00004850-199807000-00002
10.1111/j.1532-5415.1999.tb01898.x
10.2165/00003495-199040020-00008
10.1056/NEJM199809243391303
10.1016/0140-6736(92)91935-2
10.1093/ajhp/53.21.2638
10.1056/NEJM198702123160702
10.2165/00002018-199513040-00005
10.2165/00003088-199529030-00002
10.1111/j.1532-5415.1999.tb01603.x
10.1016/S0091-3057(98)00102-6
10.1345/aph.17111
10.1016/0140-6736(93)92862-N
10.1016/0021-9681(87)90171-8
10.1016/0895-4356(92)90133-8
10.5694/j.1326-5377.1993.tb121839.x
10.1001/archinte.155.16.1801
10.1177/106002809703100518
10.1001/archinte.151.9.1779
10.1001/jama.272.22.1721
ContentType Journal Article
Copyright 2002 INIST-CNRS
Copyright Lippincott Williams & Wilkins Dec 2001
Copyright_xml – notice: 2002 INIST-CNRS
– notice: Copyright Lippincott Williams & Wilkins Dec 2001
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7TK
K9.
NAPCQ
7QJ
7X8
DOI 10.1111/j.1532-5415.2001.49280.x
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Applied Social Sciences Index & Abstracts (ASSIA)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Applied Social Sciences Index and Abstracts (ASSIA)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Applied Social Sciences Index and Abstracts (ASSIA)
ProQuest Health & Medical Complete (Alumni)

CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1532-5415
EndPage 1690
ExternalDocumentID 98663536
11844004
13413514
10_1111_j_1532_5415_2001_49280_x
JGS49280
ark_67375_WNG_XN3N89PZ_B
Genre shortCommunication
Research Support, U.S. Gov't, P.H.S
Journal Article
Comparative Study
Feature
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: R01 DA100014-01
– fundername: NIA NIH HHS
  grantid: R03-AG 18395
GroupedDBID ---
--Z
-~X
..I
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1CY
1KJ
1OB
1OC
29L
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8F7
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AAQQT
AASGY
AAWTL
AAXRX
AAYCA
AAYJJ
AAZKR
ABCQN
ABCUV
ABDPE
ABEML
ABIVO
ABJNI
ABLJU
ABOCM
ABPPZ
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFO
ACGFS
ACGOF
ACHQT
ACMXC
ACNCT
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHMBA
AI.
AIACR
AIAGR
AIDQK
AIDYY
AIQQE
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BKOMP
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
DUUFO
EBS
EJD
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
H~9
IHE
IX1
J0M
J5H
K48
KBYEO
L7B
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NF~
NHB
O66
O9-
OHT
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TAE
TEORI
TN5
TWZ
UB1
UKR
UPT
V9Y
VH1
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQ9
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
XOL
YF5
YFH
YOC
YQJ
YQT
YUY
YZZ
ZGI
ZHY
ZXP
ZY1
ZZTAW
~IA
~S-
~WT
AAHHS
AARRQ
ACCFJ
AEEZP
AEQDE
AEUQT
AFPWT
AIWBW
AJBDE
EMOBN
ESX
QN7
WRC
YCJ
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
PKN
YIN
Z5M
7QP
7TK
K9.
NAPCQ
7QJ
7X8
ID FETCH-LOGICAL-c5580-23cd9940b4a25c152c1e2515e7f3b29ad8409c21d08c1d93b10de7bd9a89a6a13
IEDL.DBID DR2
ISSN 0002-8614
IngestDate Sun Sep 28 06:37:13 EDT 2025
Sun Sep 28 06:32:39 EDT 2025
Fri Jul 25 08:32:47 EDT 2025
Wed Feb 19 02:35:58 EST 2025
Tue Jul 01 05:45:04 EDT 2025
Tue Jul 01 02:50:52 EDT 2025
Thu Apr 24 23:07:33 EDT 2025
Wed Jan 22 16:58:04 EST 2025
Sun Sep 21 06:18:17 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Human
Femoral neck
Diseases of the osteoarticular system
Hypnotic
Fracture
Case control study
Trauma
Hip
Recommendation
Medical prescription
Risk factor
Secondary effect
Zolpidem
Fall
Bone
Elderly
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5580-23cd9940b4a25c152c1e2515e7f3b29ad8409c21d08c1d93b10de7bd9a89a6a13
Notes istex:5AFFC27AA0CFA927C17A9EE6B3AD547A6D5D0762
ArticleID:JGS49280
ark:/67375/WNG-XN3N89PZ-B
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
PMID 11844004
PQID 210384632
PQPubID 41968
PageCount 6
ParticipantIDs proquest_miscellaneous_72439346
proquest_miscellaneous_57818923
proquest_journals_210384632
pubmed_primary_11844004
pascalfrancis_primary_13413514
crossref_primary_10_1111_j_1532_5415_2001_49280_x
crossref_citationtrail_10_1111_j_1532_5415_2001_49280_x
wiley_primary_10_1111_j_1532_5415_2001_49280_x_JGS49280
istex_primary_ark_67375_WNG_XN3N89PZ_B
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate December 2001
PublicationDateYYYYMMDD 2001-12-01
PublicationDate_xml – month: 12
  year: 2001
  text: December 2001
PublicationDecade 2000
PublicationPlace Boston, MA, USA
PublicationPlace_xml – name: Boston, MA, USA
– name: Malden, MA
– name: United States
– name: New York
PublicationTitle Journal of the American Geriatrics Society (JAGS)
PublicationTitleAlternate Journal of the American Geriatrics Society
PublicationYear 2001
Publisher Blackwell Science Inc
Blackwell
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Science Inc
– name: Blackwell
– name: Wiley Subscription Services, Inc
References Lobo BL & Greene WL. Zolpidem: Distinct from triazolam? Ann Pharmacother 1997;31: 625-632.
American Medical Association. Physicians' Current Procedural Terminology, 4th Ed. Chicago, IL: American Medical Association, 1989.
Leipzig RM, Cummings RG, Tinetti ME. Drugs and falls in older people: A systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999;47: 30-39.
SAS Institute. SAS release 6.12. Cary, NC: SAS Institute, Inc., 1996.
International Classification of Diseases, 9th Revision, Clinical Modifications, Vol. 1. Diseases: Tabular List. Commission on Professional and Hospital Activities. Ann Arbor, MI: Edwards Brothers, 1986.
Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262: 3303-3307.DOI: 10.1001/jama.262.23.3303
Langtry HD & Benfield P. Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40: 291-313.
Baron JA, Lu-Yao G, Barrett J et al. Internal validation of Medicare claims data. Epidemiology 1994;5: 541-544.
Guerault E, Chaumet-Riffaud A, Morselli P et al. Neurological adverse event profile in elderly with zolpidem 5 mg and 10 mg: A retrospective evaluation of European phase II and III studies. J Sleep Res 1992;1(Suppl. 1):89.
Salva P & Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: Therapeutic implications. Clin Pharmacokinet 1995;29: 142-153.
Cumming RG & Klineberg RJ. Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust 1993;158: 414-417.
Mendelson WB & Jain B. An assessment of short-acting hypnotics. Drug Safety 1995;13: 257-270.
Wysowski DK & Baum C. Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Arch Intern Med 1991;151: 1779-1783.DOI: 10.1001/archinte.151.9.1779
Herings RC, Stricker BH, De Boer A et al. Benzodiazepines and the risk of hip falling leading to femur fractures. Arch Intern Med 1995;155: 1801-1807.DOI: 10.1001/archinte.155.16.1801
Charlson ME, Pompei KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987;40: 373-383.
Hajak G & Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: A post-marketing surveillance of 16,944 cases. Int Clin Psychopharmacol 1998;13: 157-167.
Psaty BM, Koepsell TD, Lin D et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999;47: 749-754.
Salzman C, ed. Clinical Geriatric Psychopharmacology, 3rd Ed. Baltimore, MD: Williams and Wilkins, 1998.
Thapa PB, Gideon P, Cost TW et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339: 875-882.DOI: 10.1056/NEJM199809243391303
Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: A review. Pharmacol Biochem Behav 1998;61: 253-269.DOI: 10.1016/S0091-3057(98)00102-6
Gericke CA & Ludolph AC. Chronic abuse of zolpidem. JAMA 1994;272: 1721-1722.DOI: 10.1001/jama.272.22.1721
Ray WA, Griffin MR, Schaffner W et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316: 363-369.
Iruela L, Ibanez-Rojo V, Baca E. Zolpidem induced macropsia in anorexic woman. Lancet 1993;342: 443-444.DOI: 10.1016/0140-6736(93)92862-N
Darcourt G, Pringuey D, Salliere D et al. The safety and tolerability of zolpidem-an update. J Psychopharmacol 1999;13: 81-93.
Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: Alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998;32: 680-691.DOI: 10.1345/aph.17111
Ansseau M, Pitchot W, Hansemme M et al. Psychotic reactions to zolpidem. Lancet 1992;339: 809.DOI: 10.1016/0140-6736(92)91935-2
Buzo Sanchez LG, Sanchez JM, Moreno JL. Dependence and tolerance with zolpidem. Am J Health Syst Pharm 1996;53: 2638.
Hoehns JD & Perry PJ. Zolpidem: A nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993;12: 814-828.
Walker AM. Observation and Inference: An Introduction to the Methods of Epidemiology. Newton Lower Falls, MA: Epidemiology Resources, 1991, pp 119-128.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45: 613-619.DOI: 10.1016/0895-4356(92)90133-8
Jonas JM, Coleman BS, Sheridan AQ et al. Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. J Clin Psychiatry 1992;53(Suppl):19-31.
Allain H & Monti J. General safety profile of zolpidem: Safety in elderly, overdose and rebound effects. Eur Psychiatry 1997;12(Suppl. 1):21S-29S.DOI: 10.1016/S0924-9338(97)80017-X
1991; 151
1995; 13
1999; 47
1994; 272
1998; 339
1998
1996
1994
1995; 155
1998; 61
1991
1992; 53
1996; 53
1993; 342
1990; 40
1993; 12
1987; 40
1997; 31
1989; 262
1987; 316
1997; 12
1999; 13
1986
1992; 339
1995; 29
1993; 158
1998; 32
1992; 45
1992; 1
1994; 5
1989
1988
1998; 13
International Classification of Diseases, 9th Revision, Clinical Modifications, Vol. 1 (e_1_2_6_28_2) 1986
SAS Institute (e_1_2_6_33_2) 1996
e_1_2_6_31_2
Baron JA (e_1_2_6_30_2) 1994; 5
Hoehns JD (e_1_2_6_16_2) 1993; 12
e_1_2_6_18_2
e_1_2_6_19_2
e_1_2_6_12_2
e_1_2_6_13_2
e_1_2_6_34_2
Darcourt G (e_1_2_6_11_2) 1999; 13
e_1_2_6_32_2
Guerault E (e_1_2_6_36_2) 1992; 1
e_1_2_6_17_2
e_1_2_6_14_2
e_1_2_6_15_2
Palminteri R (e_1_2_6_10_2) 1988
Salzman C (e_1_2_6_38_2) 1998
Walker AM (e_1_2_6_35_2) 1991
e_1_2_6_8_2
e_1_2_6_7_2
Griso JA (e_1_2_6_37_2) 1994
e_1_2_6_9_2
e_1_2_6_4_2
e_1_2_6_3_2
American Medical Association (e_1_2_6_29_2) 1989
e_1_2_6_6_2
e_1_2_6_5_2
e_1_2_6_23_2
e_1_2_6_2_2
e_1_2_6_22_2
e_1_2_6_21_2
Jonas JM (e_1_2_6_20_2) 1992; 53
Buzo Sanchez LG (e_1_2_6_24_2) 1996; 53
e_1_2_6_27_2
e_1_2_6_26_2
e_1_2_6_25_2
References_xml – reference: Jonas JM, Coleman BS, Sheridan AQ et al. Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. J Clin Psychiatry 1992;53(Suppl):19-31.
– reference: Thapa PB, Gideon P, Cost TW et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339: 875-882.DOI: 10.1056/NEJM199809243391303
– reference: Ray WA, Griffin MR, Schaffner W et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316: 363-369.
– reference: Hajak G & Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: A post-marketing surveillance of 16,944 cases. Int Clin Psychopharmacol 1998;13: 157-167.
– reference: Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262: 3303-3307.DOI: 10.1001/jama.262.23.3303
– reference: Walker AM. Observation and Inference: An Introduction to the Methods of Epidemiology. Newton Lower Falls, MA: Epidemiology Resources, 1991, pp 119-128.
– reference: Leipzig RM, Cummings RG, Tinetti ME. Drugs and falls in older people: A systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999;47: 30-39.
– reference: Buzo Sanchez LG, Sanchez JM, Moreno JL. Dependence and tolerance with zolpidem. Am J Health Syst Pharm 1996;53: 2638.
– reference: Wysowski DK & Baum C. Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Arch Intern Med 1991;151: 1779-1783.DOI: 10.1001/archinte.151.9.1779
– reference: Allain H & Monti J. General safety profile of zolpidem: Safety in elderly, overdose and rebound effects. Eur Psychiatry 1997;12(Suppl. 1):21S-29S.DOI: 10.1016/S0924-9338(97)80017-X
– reference: Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: A review. Pharmacol Biochem Behav 1998;61: 253-269.DOI: 10.1016/S0091-3057(98)00102-6
– reference: Psaty BM, Koepsell TD, Lin D et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999;47: 749-754.
– reference: Hoehns JD & Perry PJ. Zolpidem: A nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993;12: 814-828.
– reference: Langtry HD & Benfield P. Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40: 291-313.
– reference: Baron JA, Lu-Yao G, Barrett J et al. Internal validation of Medicare claims data. Epidemiology 1994;5: 541-544.
– reference: Cumming RG & Klineberg RJ. Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust 1993;158: 414-417.
– reference: Salva P & Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: Therapeutic implications. Clin Pharmacokinet 1995;29: 142-153.
– reference: American Medical Association. Physicians' Current Procedural Terminology, 4th Ed. Chicago, IL: American Medical Association, 1989.
– reference: Gericke CA & Ludolph AC. Chronic abuse of zolpidem. JAMA 1994;272: 1721-1722.DOI: 10.1001/jama.272.22.1721
– reference: Lobo BL & Greene WL. Zolpidem: Distinct from triazolam? Ann Pharmacother 1997;31: 625-632.
– reference: Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45: 613-619.DOI: 10.1016/0895-4356(92)90133-8
– reference: Iruela L, Ibanez-Rojo V, Baca E. Zolpidem induced macropsia in anorexic woman. Lancet 1993;342: 443-444.DOI: 10.1016/0140-6736(93)92862-N
– reference: Darcourt G, Pringuey D, Salliere D et al. The safety and tolerability of zolpidem-an update. J Psychopharmacol 1999;13: 81-93.
– reference: Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: Alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998;32: 680-691.DOI: 10.1345/aph.17111
– reference: Mendelson WB & Jain B. An assessment of short-acting hypnotics. Drug Safety 1995;13: 257-270.
– reference: Ansseau M, Pitchot W, Hansemme M et al. Psychotic reactions to zolpidem. Lancet 1992;339: 809.DOI: 10.1016/0140-6736(92)91935-2
– reference: Guerault E, Chaumet-Riffaud A, Morselli P et al. Neurological adverse event profile in elderly with zolpidem 5 mg and 10 mg: A retrospective evaluation of European phase II and III studies. J Sleep Res 1992;1(Suppl. 1):89.
– reference: Charlson ME, Pompei KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987;40: 373-383.
– reference: International Classification of Diseases, 9th Revision, Clinical Modifications, Vol. 1. Diseases: Tabular List. Commission on Professional and Hospital Activities. Ann Arbor, MI: Edwards Brothers, 1986.
– reference: SAS Institute. SAS release 6.12. Cary, NC: SAS Institute, Inc., 1996.
– reference: Herings RC, Stricker BH, De Boer A et al. Benzodiazepines and the risk of hip falling leading to femur fractures. Arch Intern Med 1995;155: 1801-1807.DOI: 10.1001/archinte.155.16.1801
– reference: Salzman C, ed. Clinical Geriatric Psychopharmacology, 3rd Ed. Baltimore, MD: Williams and Wilkins, 1998.
– volume: 13
  start-page: 257
  year: 1995
  end-page: 270
  article-title: An assessment of short‐acting hypnotics.
  publication-title: Drug Safety
– volume: 29
  start-page: 142
  year: 1995
  end-page: 153
  article-title: Clinical pharmacokinetics and pharmacodynamics of zolpidem: Therapeutic implications.
  publication-title: Clin Pharmacokinet
– volume: 1
  start-page: 89
  issue: Suppl. 1
  year: 1992
  article-title: Neurological adverse event profile in elderly with zolpidem 5 mg and 10 mg: A retrospective evaluation of European phase II and III studies.
  publication-title: J Sleep Res
– year: 1989
– volume: 158
  start-page: 414
  year: 1993
  end-page: 417
  article-title: Psychotropics, thiazide diuretics and hip fractures in the elderly.
  publication-title: Med J Aust
– volume: 155
  start-page: 1801
  year: 1995
  end-page: 1807
  article-title: Benzodiazepines and the risk of hip falling leading to femur fractures.
  publication-title: Arch Intern Med
– start-page: 1321
  year: 1994
  end-page: 1336
– volume: 151
  start-page: 1779
  year: 1991
  end-page: 1783
  article-title: Outpatient use of prescription sedative‐hypnotic drugs in the United States, 1970 through 1989.
  publication-title: Arch Intern Med
– volume: 31
  start-page: 625
  year: 1997
  end-page: 632
  article-title: Zolpidem: Distinct from triazolam?
  publication-title: Ann Pharmacother
– volume: 40
  start-page: 291
  year: 1990
  end-page: 313
  article-title: Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.
  publication-title: Drugs
– year: 1996
– volume: 53
  start-page: 19
  issue: Suppl
  year: 1992
  end-page: 31
  article-title: Comparative clinical profiles of triazolam versus other shorter‐acting hypnotics.
  publication-title: J Clin Psychiatry
– volume: 13
  start-page: 81
  year: 1999
  end-page: 93
  article-title: The safety and tolerability of zolpidem—an update.
  publication-title: J Psychopharmacol
– volume: 40
  start-page: 373
  year: 1987
  end-page: 383
  article-title: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation.
  publication-title: J Chron Dis
– year: 1998
– volume: 32
  start-page: 680
  year: 1998
  end-page: 691
  article-title: Beyond benzodiazepines: Alternative pharmacologic agents for the treatment of insomnia.
  publication-title: Ann Pharmacother
– year: 1986
– volume: 13
  start-page: 157
  year: 1998
  end-page: 167
  article-title: Safety and tolerance of zolpidem in the treatment of disturbed sleep: A post‐marketing surveillance of 16,944 cases.
  publication-title: Int Clin Psychopharmacol
– volume: 47
  start-page: 30
  year: 1999
  end-page: 39
  article-title: Drugs and falls in older people: A systematic review and meta‐analysis: I. Psychotropic drugs.
  publication-title: J Am Geriatr Soc
– volume: 45
  start-page: 613
  year: 1992
  end-page: 619
  article-title: Adapting a clinical comorbidity index for use with ICD‐9‐CM administrative databases.
  publication-title: J Clin Epidemiol
– volume: 12
  start-page: 814
  year: 1993
  end-page: 828
  article-title: Zolpidem: A nonbenzodiazepine hypnotic for treatment of insomnia.
  publication-title: Clin Pharm
– volume: 5
  start-page: 541
  year: 1994
  end-page: 544
  article-title: Internal validation of Medicare claims data.
  publication-title: Epidemiology
– volume: 47
  start-page: 749
  year: 1999
  end-page: 754
  article-title: Assessment and control for confounding by indication in observational studies.
  publication-title: J Am Geriatr Soc
– year: 1988
– volume: 342
  start-page: 443
  year: 1993
  end-page: 444
  article-title: Zolpidem induced macropsia in anorexic woman.
  publication-title: Lancet
– volume: 61
  start-page: 253
  year: 1998
  end-page: 269
  article-title: Behavioral pharmacology of zolpidem relative to benzodiazepines: A review.
  publication-title: Pharmacol Biochem Behav
– volume: 316
  start-page: 363
  year: 1987
  end-page: 369
  article-title: Psychotropic drug use and the risk of hip fracture.
  publication-title: N Engl J Med
– volume: 339
  start-page: 875
  year: 1998
  end-page: 882
  article-title: Antidepressants and the risk of falls among nursing home residents.
  publication-title: N Engl J Med
– volume: 262
  start-page: 3303
  year: 1989
  end-page: 3307
  article-title: Benzodiazepines of long and short elimination half‐life and the risk of hip fracture.
  publication-title: JAMA
– volume: 12
  start-page: 21S
  issue: Suppl. 1
  year: 1997
  end-page: 29S
  article-title: General safety profile of zolpidem: Safety in elderly, overdose and rebound effects.
  publication-title: Eur Psychiatry
– volume: 339
  start-page: 809
  year: 1992
  article-title: Psychotic reactions to zolpidem.
  publication-title: Lancet
– volume: 53
  start-page: 2638
  year: 1996
  article-title: Dependence and tolerance with zolpidem.
  publication-title: Am J Health Syst Pharm
– volume: 272
  start-page: 1721
  year: 1994
  end-page: 1722
  article-title: Chronic abuse of zolpidem.
  publication-title: JAMA
– start-page: 119
  year: 1991
  end-page: 128
– volume: 12
  start-page: 814
  year: 1993
  ident: e_1_2_6_16_2
  article-title: Zolpidem: A nonbenzodiazepine hypnotic for treatment of insomnia.
  publication-title: Clin Pharm
– ident: e_1_2_6_27_2
– volume: 13
  start-page: 81
  year: 1999
  ident: e_1_2_6_11_2
  article-title: The safety and tolerability of zolpidem—an update.
  publication-title: J Psychopharmacol
  doi: 10.1177/026988119901300109
– ident: e_1_2_6_6_2
  doi: 10.1001/jama.262.23.3303
– ident: e_1_2_6_22_2
  doi: 10.1016/S0924-9338(97)80017-X
– ident: e_1_2_6_13_2
– ident: e_1_2_6_21_2
  doi: 10.1097/00004850-199807000-00002
– volume: 1
  start-page: 89
  issue: 1
  year: 1992
  ident: e_1_2_6_36_2
  article-title: Neurological adverse event profile in elderly with zolpidem 5 mg and 10 mg: A retrospective evaluation of European phase II and III studies.
  publication-title: J Sleep Res
– volume-title: Clinical Geriatric Psychopharmacology
  year: 1998
  ident: e_1_2_6_38_2
– volume-title: Imidazopyridines in Sleep Disorders
  year: 1988
  ident: e_1_2_6_10_2
– volume: 53
  start-page: 19
  year: 1992
  ident: e_1_2_6_20_2
  article-title: Comparative clinical profiles of triazolam versus other shorter‐acting hypnotics.
  publication-title: J Clin Psychiatry
– ident: e_1_2_6_4_2
  doi: 10.1111/j.1532-5415.1999.tb01898.x
– volume-title: Diseases: Tabular List. Commission on Professional and Hospital Activities
  year: 1986
  ident: e_1_2_6_28_2
– ident: e_1_2_6_12_2
– ident: e_1_2_6_19_2
  doi: 10.2165/00003495-199040020-00008
– ident: e_1_2_6_3_2
  doi: 10.1056/NEJM199809243391303
– ident: e_1_2_6_23_2
  doi: 10.1016/0140-6736(92)91935-2
– volume: 53
  start-page: 2638
  year: 1996
  ident: e_1_2_6_24_2
  article-title: Dependence and tolerance with zolpidem.
  publication-title: Am J Health Syst Pharm
  doi: 10.1093/ajhp/53.21.2638
– volume-title: Physicians' Current Procedural Terminology
  year: 1989
  ident: e_1_2_6_29_2
– volume: 5
  start-page: 541
  year: 1994
  ident: e_1_2_6_30_2
  article-title: Internal validation of Medicare claims data.
  publication-title: Epidemiology
– ident: e_1_2_6_5_2
  doi: 10.1056/NEJM198702123160702
– ident: e_1_2_6_17_2
  doi: 10.2165/00002018-199513040-00005
– ident: e_1_2_6_9_2
  doi: 10.2165/00003088-199529030-00002
– start-page: 119
  volume-title: Observation and Inference: An Introduction to the Methods of Epidemiology
  year: 1991
  ident: e_1_2_6_35_2
– ident: e_1_2_6_34_2
  doi: 10.1111/j.1532-5415.1999.tb01603.x
– ident: e_1_2_6_14_2
  doi: 10.1016/S0091-3057(98)00102-6
– ident: e_1_2_6_18_2
  doi: 10.1345/aph.17111
– ident: e_1_2_6_26_2
  doi: 10.1016/0140-6736(93)92862-N
– ident: e_1_2_6_32_2
  doi: 10.1016/0021-9681(87)90171-8
– ident: e_1_2_6_31_2
  doi: 10.1016/0895-4356(92)90133-8
– start-page: 1321
  volume-title: Principles of Geriatric Medicine and Gerontology
  year: 1994
  ident: e_1_2_6_37_2
– ident: e_1_2_6_7_2
  doi: 10.5694/j.1326-5377.1993.tb121839.x
– ident: e_1_2_6_8_2
  doi: 10.1001/archinte.155.16.1801
– ident: e_1_2_6_15_2
  doi: 10.1177/106002809703100518
– ident: e_1_2_6_2_2
  doi: 10.1001/archinte.151.9.1779
– ident: e_1_2_6_25_2
  doi: 10.1001/jama.272.22.1721
– volume-title: SAS release 6.12
  year: 1996
  ident: e_1_2_6_33_2
SSID ssj0012088
Score 2.170826
Snippet OBJECTIVES: The widespread use of sedative‐hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer...
OBJECTIVES: The widespread use of sedative‐hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer...
The widespread use of sedative-hypnotics in older populations makes it imperative to identify hazardous regimens that should be avoided and safer regimens that...
Although benzodiazepines have been shown to increase fall and fracture risk, zolpidem, a nonbenzodiazepine hypnotic has been advocated as a safer alternative....
SourceID proquest
pubmed
pascalfrancis
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1685
SubjectTerms Aged
Aged, 80 and over
Aging - drug effects
Antidepressive Agents - adverse effects
Antipsychotic Agents - adverse effects
Benzodiazepines - adverse effects
Benzothiadiazines
Biological and medical sciences
Case-Control Studies
Diuretics
Elderly people
Falls
Female
Fractured hips
Fractures
hip fracture
Hip Fractures - chemically induced
Hip Fractures - surgery
Humans
Hypnotics
Hypnotics and Sedatives - adverse effects
Length of Stay
Male
Medical sciences
Neuropharmacology
Odds Ratio
older
Older people
Pharmacology. Drug treatments
Prescription drugs
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Psychotropic Drugs - adverse effects
Pyridines - adverse effects
Retrospective Studies
Risk Factors
sedative-hypnotics
Sodium Chloride Symporter Inhibitors - adverse effects
USA
Zolpidem
Title Zolpidem Use and Hip Fractures in Older People
URI https://api.istex.fr/ark:/67375/WNG-XN3N89PZ-B/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1532-5415.2001.49280.x
https://www.ncbi.nlm.nih.gov/pubmed/11844004
https://www.proquest.com/docview/210384632
https://www.proquest.com/docview/57818923
https://www.proquest.com/docview/72439346
Volume 49
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 0002-8614
  databaseCode: DR2
  dateStart: 20010101
  customDbUrl:
  isFulltext: true
  eissn: 1532-5415
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0012088
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlhdJL3w83bapD6c3GetnSsS3dLIFsQ9ulSy5Cr4WwwRviXQj99dXIXqcuKYTSm8GWhUYzmm-kTzMIvRPUUaZCyKM34TlXPOTS2JAHWvmKBmt94uYcz6rpnB8txKLnP8FdmC4_xLDhBpaR1mswcGPbsZELBnn8iYAwjxRcUVkWgCcJE-nE9uuQSYrQUsoBCUeXNCb13Pijkae6C0K_AuakaaPwll3Vi5tg6RjlJjc1eYhWuwF27JRVsd3Ywv38I_fj_5HAI_SgR7P4Q6d-j9Gd0DxB94778_qnqDhdn6cStHjeBmwaj6dnF3gCN7O2Mc7HZw3-AmXC8Ukisj9D88nn75-meV-hIXdCyDKnzHmleGm5ocJFKOBIiIBJhHrJLFXGQ_joKPGldMQrZknpQ229MlKZyhD2HO016ya8RNgbHyNN5T1ssChwksbXTFjIF-jZkmSo3s2Gdn36cqiica5_C2OiODSIA4prEp3Eoa8yRIaWF10Kj1u0eZ8mfGhgLldAgauF_jE71IsZm0l1cqo_ZuhgpBHXPQA8iPqfof2diuh-eWg1hbT0vGI0Q2-Ht9Gu4bDGNGG9bXVcSYmM6PvvX9Q0gknGqwy96DTvuu8YtsPaHGWW9OfWw9ZHh9_S46t_brmP7ieaXmL8vEZ7m8tteBNx28YeJIv8Bf1mLak
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED-hTQJeYHyNsLHlAfGWKLbjJH6Eja6MNUywimovlh270rQqndZWmvjr8TlpRtCQJsRbpORi-Xwfv7PPdwDvOK0oE9ZGzpukUSpSGxVK28jSzGTUam18bs6ozIbj9HjCJ207ILwL09SH6DbcUDO8vUYFxw3pvpZzhoX8Ccc4j8SpoEUSO0C5icd1qKWH37paUoQmRdFhYeeU-mk9d_6p56s2ke03mDupFo5906bvxV3AtI9zvaMaPIXZeopNfsplvFrquPr5R_XH_8SDLXjSAtrwQyOBz-CBrZ_Dw1F7ZP8C4vP5zHehDccLG6rahMOLq3CAl7NWLtQPL-rwK3YKD099LvtLGA8-nR0Mo7ZJQ1RxXiQRZZURIk10qiivHBqoiHWYidt8yjQVymAEWVFikqIiRjBNEmNzbYQqhMoUYa9go57X9jWERhkXbApjcI9FoJ9UJmdcY8lAw6YkgHy9HLJqK5hjI42Z_C2SceyQyA7sr0mkZ4e8CYB0lFdNFY970Lz3K94RqOtLzILLufxRHslJycpCnJ7LjwHs9UTidgRECE4FAthZy4hsLcRCUqxMn2aMBrDfvXWqjec1qrbz1UI6Y0oKB8D__kVOHZ5kaRbAdiN6t2O7yB3Ns-OZF6B7T1seH333j2_-mXIfHg3PRify5HP5ZQce-6w9nwC0CxvL65V962DcUu959fwF63gxxQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9swED9GC2Uv-97qdWv9MPbmYH3Z1uO-0qxbvbAtLPRFSJYCJcUJTQJlf_10suPOo4My9mawZaHTne530k93AK8ErSiTziXem_CES-6SQhuXOJrZjDpjbODmnJbZaMJPpmLa8p_wLkyTH6LbcEPLCOs1GvjSzvpGLhjm8ScCwzwy4JIW6cDjyV2e-WALAdLXLpUUoWlRdFDY-6Q-q-fGP_Vc1S5K_Qqpk3rlpTdryl7chEv7MDf4qeF9mG9H2NBT5oPN2gyqn38kf_w_IngA91o4G79p9O8h3HH1I9g7bQ_sH8PgbHERatDGk5WLdW3j0fkyHuLVrI0P9OPzOv6CdcLjcWCyP4HJ8MP3d6OkLdGQVEIUaUJZZaXkqeGaispjgYo4j5iEy2fMUKktxo8VJTYtKmIlMyS1LjdW6kLqTBP2FHbqRe32Ibba-lBTWos7LBK9pLY5EwYTBlo2IxHk29lQVZu_HMtoXKjf4hgvDoXiwOqaRAVxqKsISNdy2eTwuEWb12HCuwb6co4cuFyoH-WxmpasLOT4TL2N4LCnEdc9ID7wBhDBwVZFVLs-rBTFvPQ8YzSCo-6tN2w8rdG1W2xWyi-lpPDw--9f5NSjScazCJ41mnfdt4_bcXH2Mgv6c-thq5Pjb-Hx-T-3PIK98fuh-vyx_HQAdwNlL7B_XsDO-nLjXnoMtzaHwTh_AQ0xMHQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Zolpidem+Use+and+hip+fractures+in+older+people&rft.jtitle=Journal+of+the+American+Geriatrics+Society+%28JAGS%29&rft.au=WANG%2C+Philip+S&rft.au=BOHN%2C+Rhonda+L&rft.au=GLYNN%2C+Robert+J&rft.au=MOGUN%2C+Helen&rft.date=2001-12-01&rft.pub=Blackwell&rft.issn=0002-8614&rft.volume=49&rft.issue=12&rft.spage=1685&rft.epage=1690&rft_id=info:doi/10.1111%2Fj.1532-5415.2001.49280.x&rft.externalDBID=n%2Fa&rft.externalDocID=13413514
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-8614&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-8614&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-8614&client=summon